Innoviva Specialty Therapeutics
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II), was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2017. We look forward to meeting you at the GIAPREZA exhibit 3038. For more information visit www.giapreza.com